TrialJAMA neurology2022

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.

Sergey Shcherbinin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.